Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Articles, expert interviews, and insights from life sciences leaders
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Read interview: Healthcare Supply Chains in Africa: Lessons from COVID-19
Read interview: How Cortical Implants Are Opening a New Era of Vision Restoration
Read interview: How Clinical Research Shapes Cardiac Device Innovation
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Reimagine AI-driven Drug Discovery with Pharma Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
How Pharmacy Innovation Is Changing Healthcare Delivery
Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.
Phenotypic Drug Discovery: Beyond the Target
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
How AI Is Reshaping Clinical Trials in HealthTech
Trisha Pillay speaks with Adriaan Kruger, CEO of nuvoteQ, as they unpack why clinical research is still heavily reliant on paper-based systems in many regions.
Drug Discovery and Pharmacoinformatics in 2026
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
Modern Drug Discovery Challenges Demand a New Pharma Paradigm
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.
Close the Drug Discovery Loop by Leveraging the DMTA Cycle
The DMTA cycle is the engine of modern pharma R&D. Learn how integrated DMTA workflows reduce early-stage attrition and compress drug discovery timelines.
